On October 7, 2024 Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, reported that it will present a poster highlighting median 24-month follow up from the ongoing randomized Phase I trial of its individualized therapeutic cancer vaccine, TG4050 at the 39th Society for ImmunoTherapy of Cancer (SITC) (Free SITC Whitepaper) annual meeting (Press release, Transgene, OCT 7, 2024, View Source [SID1234647066]). This presentation will emphasize efficacy and disease-free survival outcomes in patients with head and neck cancers. SITC (Free SITC Whitepaper) annual meeting will take place in Houston, Texas, USA, from November 6 to 10, 2024.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract will be available on the SITC (Free SITC Whitepaper) website on November 5, 2024, from 3 p.m. CET.
Poster details
Title: "Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC)".
Poster and abstract number: 650
Date and Time: Thursday, November 7, 2024 at 4 p.m. CET
Author: C. Le Tourneau
TG4050 is an individualized immunotherapy being developed for solid tumors that is based on Transgene’s myvac technology and powered by NEC’s longstanding artificial intelligence (AI) expertise. TG4050 is being evaluated in a randomized multicenter Phase I/II clinical trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers (NCT04183166).
Transgene previously presented data in April 2024, that showed that all patients who received TG4050 remained disease-free after a median follow-up of 18.6 months, comparing favorably to the observational arm which saw 3 out of 16 patients relapse during the same time period.
Transgene and NEC are continuing the joint development of TG4050 in this indication with a Phase II extension of the trial, which is currently enrolling patients.